A Novel Antimicrobial Peptide Sparamosin26–54 From the Mud Crab Scylla paramamosain Showing Potent Antifungal Activity Against Cryptococcus neoformans

Due to the increasing prevalence of drug-resistant fungi and the limitations of current treatment strategies to fungal infections, exploration and development of new antifungal drugs or substituents are necessary. In the study, a novel antimicrobial peptide, named Sparamosin, was identified in the mud crab Scylla paramamosain, which contains a signal peptide of 22 amino acids and a mature peptide of 54 amino acids. The antimicrobial activity of its synthetic mature peptide and two truncated peptides (Sparamosin1–25 and Sparamosin26–54) were determined. The results showed that Sparamosin26–54 had the strongest activity against a variety of Gram-negative bacteria, Gram-positive bacteria and fungi, in particular had rapid fungicidal kinetics (killed 99% Cryptococcus neoformans within 10 min) and had potent anti-biofilm activity against C. neoformans, but had no cytotoxic effect on mammalian cells. The RNA-seq results showed that after Sparamosin26–54 treatment, the expression of genes involved in cell wall component biosynthesis, cell wall integrity signaling pathway, anti-oxidative stress, apoptosis and DNA repair were significantly up-regulated, indicating that Sparamosin26–54 might disrupt the cell wall of C. neoformans, causing oxidative stress, DNA damage and cell apoptosis. The underlying mechanism was further confirmed. Sparamosin26–54 could bind to several phospholipids in the cell membrane and effectively killed C. neoformans through disrupting the integrity of the cell wall and cell membrane observed by electron microscope and staining assay. In addition, it was found that the accumulation of reactive oxygen species (ROS) increased, the mitochondrial membrane potential (MMP) was disrupted, and DNA fragmentation was induced after Sparamosin26–54 treatment, which are all hallmarks of apoptosis. Taken together, Sparamosin26–54 has a good application prospect as an effective antimicrobial agent, especially for C. neoformans infections.


INTRODUCTION
In addition to the serious threats caused by various virus outbreaks and drug-resistant bacterial infections, fungal infections are also similar headlines today. It is estimated that more than 1 billion people worldwide suffer from fungal diseases (Felix et al., 2017). Most fungal diseases are superficial infections of the skin and nails and mucosal infections of the oral cavity and genital tract, which are readily to diagnose and treat (Brown et al., 2012;Denning and Bromley, 2015). Invasive fungal infections mainly occur in immunocompromised patients, such as those infected with HIV or undergoing chemotherapy, which is associated with unacceptably high mortality (Miceli et al., 2011). It is estimated that nearly 2 million people die from fungal infections each year, and the death toll continues to rise (Pappas et al., 2010;Brown et al., 2012). About 90% of these deaths are caused by species belonging to one of the following four genera: Cryptococcus, Candida, Aspergillus, and Pneumocystis. C. neoformans is an opportunistic pathogen that exists widely in the environment and is one of the main species causing life-threatening cryptococcal meningitis. Globally, an estimated 223,100 cases of cryptococcal meningitis occur each year, resulting in 181,100 deaths (Rajasingham et al., 2017). Most deaths are reported to occur in low-and middle-income countries due to the lack of essential medicines and the high cost of effective treatment (Loyse et al., 2019).
In the past decades, a series of topical drugs have been used and moderate success has been achieved in the control of many superficial and mucosal infections. However, few drugs are available for invasive fungal infections (Perfect, 2017). Antifungal drugs are more difficult to develop than antibacterial drugs, because fungi are eukaryotes and have a high degree of similarity with mammalian cells, which means that there are relatively few differential targets to be exploited for antifungal drug development (Denning and Bromley, 2015). Currently, only four types of antifungal drugs (polyenes, flucytosine, azoles, and echinocandins) are used orally or intravenously for the treatment of invasive fungal infections in humans (Perfect, 2017). Although existing antifungal drugs are clinically useful, they do have some limitations, such as the development of drug resistance, undesirable side effects and host toxicity. The best example is the polyene antibiotic, amphotericin B, which was first isolated from the fermenter cultures of Streptomyces nodosus in 1959 (Dutcher et al., 1959). Amphotericin B has a relatively broad spectrum of action, and is still the drug of choice against serious infections with fungi such as C. neoformans, Candida albicans, or Aspergillus fumigatus (Lemke et al., 2005;Iyer et al., 2021). Like other polyene antibiotics, amphotericin B preferentially binds to ergosterol, which is the main sterol in fungal cell membranes, resulting in the disruption of cell membrane integrity (Campoy and Adrio, 2017). However, fungi can develop resistance to amphotericin B by reducing the content of ergosterol in the cell membrane. In recent years, some amphotericin B-resistant strains have been reported, including C. neoformans, C. albicans, and A. fumigatus (Ellis, 2002;Perlin et al., 2017). In addition, the adverse effects of amphotericin B are common, with nephrotoxicity being the most serious side effect (Fanos and Cataldi, 2000). Therefore, new antifungal agents are urgently needed to address the global threats of fungal pathogens and the limitations of existing antifungal drugs.
Antimicrobial peptides (AMPs) are considered to be natural antibiotics, which can be found in animals, plants and microorganisms, and function as the first line of host defense against the invasion of exogenous pathogen (Zasloff, 2002;Peschel and Sahl, 2006). They exert broad spectrum of activity against Gram-negative and Gram-positive bacteria, fungi, parasites, viruses and even antibiotic-resistant strains. The typical mechanism of AMPs action is to interact with cell membrane of microorganism through electrostatic interactions, causing membrane disruption, cytoplasmic leakage, and ultimately cell death. The proposed membrane disruption models include barrel-stave model, carpet model and toroidalpore model (Brogden, 2005). Some AMPs also interfere with many important cellular functions, such as inhibition of cell wall synthesis, inhibition of nucleic-acid synthesis, inhibition of protein synthesis, inhibition of septum formation and inhibition of enzymatic activity (Brogden, 2005). Interestingly, the antimicrobial mechanism of AMPs is different from most clinically antibiotics that only target cell membrane/wall components (Rautenbach et al., 2016). This interactions with the fundamental physiological structure and multi-target modes make it difficult for microorganisms to develop resistance (Yeung et al., 2011), making AMPs the most promising potential alternative for conventional antibiotics.
Crustaceans are a group of invertebrates that only rely on the innate immune system to defend them against invading pathogenic microorganisms. The innate immune system of crustaceans is comprised of cellular and humoral responses. In terms of humoral responses, AMPs are one of the main effectors to eliminate pathogenic microorganisms (Rowley and Powell, 2007). There is clear evidence that many AMPs with potent antibacterial activity have been isolated from crustaceans, such as anti-lipopolysaccharide factors (ALFs), Hyastatin, scygonadin, Sphistin, etc. (Wang et al., 2007;Sperstad et al., 2009b;Liu et al., 2012;Chen et al., 2015). However, the number of AMPs with effective activity against fungi is reported to be very limited. Penaeidins, a family of cationic AMPs were isolated from shrimps, such as Litopenaeus vannamei (Destoumieux et al., 1997;Gueguen et al., 2006). The recombinant penaeidins (Pen-2 and Pen-3a) exhibit not only antibacterial activity against Gram-positive bacteria, but also antifungal activity against several filamentous fungi (including Fusarium oxysporum, which caused infections in penaeid shrimps) (Destoumieux et al., 1999;Shockey et al., 2009). Crustins are another wellstudied AMPs with antifungal activity in crustaceans, which are cationic and cysteine-rich AMPs containing a whey acidic protein (WAP) domain in the C-terminus (Smith et al., 2008). A crustin gene, CruHa1 from the spider crab Hyas araneus, had moderate activity against S. cerevisiae and weak activity against C. albicans (Sperstad et al., 2009a). Several AMPs currently identified from crustaceans have antibacterial activity as well as antifungal activity, however, their antifungal mechanism has not yet been revealed. In addition, there are more new antifungal peptides from crustaceans waiting to be discovered and studied.
In this study, we screened a new antimicrobial peptide based on the transcriptome database of the mud crab S. paramamosain established in our laboratory, and named it Sparamosin. The full-length cDNA sequence of Sparamosin gene was obtained. Sparamosin mature peptide and its two truncated peptides (Sparamosin 1−25 and Sparamosin 26−54 ) were chemically synthesized, and their in vitro antimicrobial activity were determined. Among these three peptides, Sparamosin 26−54 showed the strongest antimicrobial activity, which was used to carry out a series of follow-up studies, such as evaluating its anti-biofilm activity. To investigate the antifungal mechanism of Sparamosin 26−54 against C. neoformans, RNA-seq was used to identify the differentially expressed genes and the pathways involved. Confocal laser scanning microscopy, scanning electron microscope and transmission electron microscope were used to provide further evidence on the antifungal mechanism of Sparamosin 26−54 against C. neoformans. This study will provide basic information for the development of new antifungal drugs.

Animals and Microorganisms
Mud crabs (S. paramamosain) were obtained from Zhangpu Fish Farm (Fujian, China), and testes from male crabs (body weight 300 ± 10 g) were used for RNA extraction. The bacterial strains were cultured in nutrient broth at 37 • C, and the fungal strains were grown in potato dextrose agar (PDA) at 28 • C. All experiments were carried out in strict accordance with the guidelines of the standard biosecurity and institutional safety procedures established by Xiamen University.

Cloning the Full-Length cDNA of Sparamosin
Rapid amplification of cDNA ends (RACE) PCR was performed to obtain the full-length cDNA of Sparamosin. Total RNA from the testes of normal mature crabs was extracted using TRIzol TM reagent (Invitrogen, United States) and cDNA was synthesized using PrimeScript TM RT reagent Kit with a gDNA Eraser Kit (Takara, China). In addition, RACE cDNA was prepared using SMARTer R RACE 5 /3 Kit (Takara, China) and was used as a template for PCR. Gene-specific primers (Supplementary Table 1) were designed based on the obtained partial cDNA sequence from transcriptome database established by our laboratory to amplify the target gene, and the fragment was recombined into pMD18-T Vector (Takara, China) and sequenced by Bioray biotechnology (Xiamen, China).

Sequence Analysis, Peptides Design, and Synthesis
The signal peptide of Sparamosin was predicted by SignalP-4.1 Server 1 and the second structure of the mature peptide was predicted by PSIPRED 4.0. 2 The mature peptide was truncated between residue Ser 25 and residue Gly 26 to evaluate the antimicrobial activity of different helical regions. The physicochemical parameters of the peptides, such as molecular weight, theoretical isoelectric point, net positive charge and hydropathicity were predicted by ProtParam. 3 The total hydrophobicity was calculated through the Antimicrobial Peptide Database. 4 The peptides used in this study were chemically synthesized by Genscript (Nanjing, China). The purity and molecular weight of the peptides were further confirmed by high performance liquid chromatography and mass spectrometry, respectively. The powdered peptide could be stored for a long time at −80 • C. The stock solutions were kept at −20 • C for storage.

Antimicrobial Activity Assay
The antimicrobial activity was determined three times, each time in triplicate, in 96-well microplates according to previous reports with some modifications (Vitale et al., 2002;Wiegand et al., 2008;Castro et al., 2018). Briefly, microorganisms were harvested during their logarithmic growth phase and diluted in Mueller-Hinton broth to approximately 1 × 10 6 CFU/mL (bacteria) or diluted in RPMI 1640 medium buffered with 0.165 mol/L 3-morpholinopropane-1-sulfonic acid (pH 7.0, referred to as RPMI-MOPS) to approximately 2 × 10 4 cells/mL (yeasts or conidia of filamentous fungi). Then, the microbial suspension was added to each well and incubated with serial diluted peptides. The microplates were incubated in the dark at 37 • C for 24 h (bacteria) or at 28 • C for 48 h (yeasts or conidia of filamentous fungi). The minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and minimum fungicidal concentration (MFC) values were determined as previously described (Shan et al., 2016).

Cytotoxicity Assay
The cytotoxicity of Sparamosin 26−54 was determined on mouse hepatocytes (AML 12 cells) and human hepatocytes (L02 cells). CellTiter 96 R AQ ueous one solution Cell Proliferation assay (Promega, United States) was used to assess cell viability. Briefly, 100 µL of AML 12 or L02 cells were seeded in 96-well microplates at 10 4 cells/well and incubated at 37 • C overnight under 5% CO 2 . Then, the cells were incubated at 37 • C for 24 h in a culture medium supplemented with various concentrations of Sparamosin 26−54 (0, 0.1, 1, 10, 100 µg/mL). After incubation, the cells were treated with 20 µL of MTS-PMS reagent for another 2 h, and then the absorbance value of each well was measured at 492 nm (Tecan, Switzerland).

Biofilm Inhibition Assays
The biofilm inhibition assays were performed in 96-well microplates according to previous reports with some modifications (Berditsch et al., 2015;Poonam et al., 2017). For the biofilm formation assay, C. neoformans cells were harvested in the logarithmic phase, diluted in RPMI-MOPS medium to a final cell density of approximately 1 × 10 6 cells/mL, and then aliquoted into microplates. Serially diluted concentrations of Sparamosin 26−54 were added to the wells, and the microplates were incubated at 35 • C for 72 h without shaking to allow biofilm formation. The biofilm mass was evaluated by crystal violet (CV) staining as previously described (Berditsch et al., 2015). In experiments with preformed biofilms, C. neoformans cells were incubated at 35 • C for 72 h without shaking to allow biofilm formation. Thereafter, RPMI-MOPS medium containing Sparamosin 26−54 and resazurin (final concentration 0.1 mM) was added to the wells, and the microplates were incubated at 35 • C for another 24 h. The respiratory activity of cells in biofilm was evaluated by a modified resazurin assay as previously described (Berditsch et al., 2015).
Transcriptome Analysis of C. neoformans After Sparamosin 26−54 Treatment C. neoformans suspensions at approximately 1 × 10 7 cells/mL in RPMI-MOPS were incubated with different concentrations of Sparamosin 26−54 (6, 12 µM) at 28 • C for 1 h. Then, the cells were harvested for RNA extraction. Approximately 200 µL of freeze-dried cells were grinded in liquid nitrogen and the total RNA was isolated using TRIzol reagent. RNA-Seq was performed by Novogene Corporation (Beijing, China) using the Illumina NovaSeq platform, which could generate 150 bp paired-end reads. Reference genome and gene model annotation files of C. neoformans var. neoformans JEC21 were downloaded from GenBank (GCA_000091045.1). An index of the reference genome was constructed using Hisat2 (version 2.0.5), and pairedend clean reads were aligned with the reference genome using Hisat2 (version 2.0.5). FeatureCounts (version 1.5.0-p3) was used to calculate the number of reads mapped to each gene. The expected number of fragments per kilobase of transcript sequence per million base pairs sequenced (FPKM) for each gene was calculated based on the length of the gene and the count of reads mapped to that gene. Differential expression analysis of the two groups was performed using the DEGSeq2 R package (version 1.16.1). The p-value was adjusted using the Benjamini and Hochberg's method. The corrected p-value < 0.05 and | log 2 (Fold change)| > 1 were set as thresholds for significant differential expression. The gene ontology (GO) enrichment analysis of differentially expressed genes (DEGs) was implemented by the clusterProfiler R package (version 3.4.4).
GO terms with a corrected p-value < 0.05 were considered significantly enriched by DEGs.

Localization of Sparamosin 26−54 in C. neoformans
The analysis of the localization of Sparamosin 26−54 in C. neoformans was carried out based on the previous report with slight modifications . Briefly, C. neoformans cells were harvested in the logarithmic phase and washed with 10 mM sodium phosphate buffer (NaPB, pH 7.4). The cells were diluted in the same buffer to a final cell density of approximately 1 × 10 7 cells/mL, and incubated with 24 µM FITC-labeled Sparamosin 26−54 [synthesized by GL Biochem (Shanghai, China)] at room temperature for 30 min. After incubation, the cells were washed twice with 10 mM NaPB to remove unbound peptide. A confocal laser scanning microscopy (Zeiss, Germany) were used for imaging.

Protein-Phospholipid Interaction Assay
The polyclonal antibody of Sparamosin was prepared by GenScript (Nanjing, China) using the antigen site KVQHSIFSGLGPNPC, which was designed and optimized by OptimumAntigen Design Tool. The Sparamosin 26−54phospholipid interactions were determined using PIP Strips TM (Echelon Biosciences, United States) according to the protocol. Briefly, the membrane was blocked with 3% (wt/vol) BSA at room temperature for 1 h, and then incubated with 2 µg/mL Sparamosin 26−54 at room temperature for 1 h. Then, the membrane was incubated with Sparamosin antibody (1:1,000, diluted in 1% [wt/vol] BSA) at room temperature for 2 h. After washing with PBST several times, the membrane was then incubated with HRP conjugated goat anti-rabbit IgG (1:5,000, diluted in 1% [wt/vol] BSA) at room temperature for 40 min. The peptides were visualized on a chemiluminescent imaging system (Tanon Science and Technology, United States) using immobilon TM western chemiluminescent HRP substrate (Millipore, United States).

Time-Killing Kinetics
The time-killing kinetics assay was carried out as previous described (Shan et al., 2016). Briefly, C. neoformans cells were diluted in RPMI-MOPS medium to a final cell density of approximately 1 × 10 6 cells/mL. Sparamosin 26−54 was incubated with C. neoformans at a concentration of 1 × or 2 × MIC. The culture was sampled diluted and plated on PDA plates at different time points. After 48 h of incubation, the surviving colonies were counted, and the untreated group was used as a control. The experiments were conducted three times independently.

Scanning Electron Microscope Analysis
The effect of Sparamosin 26−54 on C. neoformans was observed using SEM as described earlier (Datta et al., 2016). Briefly, C. neoformans cells were harvested in the logarithmic phase and resuspended at approximately 1 × 10 7 cells/mL in NaPB, and incubated with 24 µM Sparamosin 26−54 at room temperature for 1 h. After incubation, the cells were fixed with 2.5% (vol/vol) glutaraldehyde at 4 • C for 2 h and washed three times before being placed on poly-L-lysine coated glass slides at 4 • C for 30 min. The cells were subsequently dehydrated in a graded series of ethanol (30, 50, 70, 90, 95, and 100%), for 15 min each. Thereafter, the samples were dehydrated with tertiary butanol followed by freezing at 4 • C and lyophilized using the critical point dryer. Finally, the specimens were coated with gold and observed under a field emission scanning electron microscope (Zeiss SUPRA 55, Germany).

Transmission Electron Microscope Analysis
The TEM analysis was carried out based on the previous report with slight modifications (Chen et al., 2003). Briefly, C. neoformans cells were prepared and incubated with Sparamosin 26−54 as described above for SEM analysis. After pre-fixation with 2.5% glutaraldehyde at 4 • C overnight, the C. neoformans cells were washed three times with NaPB and then post-fixed with 1% osmium tetroxide at 4 • C for 2.5 h. The fixed samples were washed three times with NaPB, dehydrated in a graded ethanol series (30, 50, 70, 90, and 100%), transferred to a graded mixture of absolute acetone and epoxy resin, and finally immersed in pure epoxy resin in a constant-temperature incubator overnight. Finally, the samples were sectioned using an ultramicrotome, stained with uranyl acetate and lead citrate, and observed using a transmission electron microscope (FEI, United States).

Live-Dead Staining Assay
The integrity of the cell membrane after Sparamosin 26−54 treatment was determined by live-dead staining according to the protocol of a LIVE/DEAD R FungaLight TM Yeast Viability Kit (Invitrogen, United States). Briefly, C. neoformans cells were prepared and incubated with Sparamosin 26−54 as described above for SEM analysis. After incubation, the cells were washed twice with PBS and placed on poly-L-lysine slides at room temperature for 15 min. The cells were washed twice and then stained with SYTO R 9 and PI for 15 min in the dark. Fluorescent images were obtained with a confocal laser scanning microscopy (Zeiss, Germany).

Calcein Leakage Assay
The calcein leakage assay was carried out according to a previous report with the following modifications (Vylkova et al., 2007). Briefly, C. neoformans cells were harvested in the logarithmic phase and washed with 10 mM NaPB. The cells were diluted in 10 mM NaPB to a final cell density of approximately 1 × 10 7 cells/mL and loaded with Calcein-AM (Thermo Fisher Scientific, United States) at a final concentration of 5 µM at room temperature for 2 h. Then, the cells were washed three times with 10 mM NaPB to remove unincorporated dye. Different concentrations of Sparamosin 26−54 (from 6 to 48 µM) were incubated with calcein-loaded cells in a 96-well microplate for analysis. In a microplate reader (Tecan, Switzerland), the fluorescence intensity of the induced calcein release was recorded every 15 min at the excitation and emission wavelengths of 485 nm and 530 nm, respectively. Percent leakage was calculated using the formula: percentage leakage (%) = (F sample − F 0 )/(F T − F 0 ) × 100. Where F sample is the fluorescence intensity after adding Sparamosin 26−54 , and F 0 is the fluorescence intensity determined by measuring the amount of calcein released from loaded cells without peptide treatment in 240 min, and F T is the maximum fluorescence intensity measured after the cells were boiled for 10 min. After boiling, the fluorescence intensity of calcein-loaded C. neoformans was assumed to be equal to the total potentially available intracellular calcein.

DNA and ATP Release Assay
C. neoformans suspensions at 1 × 10 7 cells/mL in RPMI-MOPS were incubated with different concentrations of Sparamosin 26−54 (6, 12, and 24 µM) at 28 • C for 0.5, 1, and 2 h. Then, the yeasts were collected by centrifugation, and the supernatant was subjected to DNA quantitative analysis in a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, United States), or an ATP determination kit (Invitrogen, United States) for quantitative analysis of ATP, as described previously (Castro et al., 2018;Liu et al., 2020).
After incubation, the cells were washed with PBS, and incubated with 2 ng of DiOC 6 (3) (Sigma, United States) at 28 • C for 30 min. The cells were then harvested and analyzed by flow cytometer (Becton Dickinson, United States).
Terminal deoxynucleotidyl transferase-mediated dUTP-nick end labeling (TUNEL) assay was carried out as described previously (Castro et al., 2018). Briefly, C. neoformans suspensions at 1 × 10 7 cells/mL in RPMI-MOPS were incubated with Sparamosin 26−54 (6, 12 µM) or amphotericin B (4 µg/mL) at 28 • C for 24 h. After incubation, the cells were washed with PBS and fixed with 2% formaldehyde in PBS at room temperature for 30 min. Then, the cells were permeabilized with 0.1% Triton X-100 for 30 min and subjected to TUNEL reaction using one step TUNEL apoptosis assay kit (Beyotime, China), according to the manufacturer's instructions. Finally, all samples were examined by fluorescence microscopy (Zeiss, Germany).

Statistical Analysis
All data were represented as mean ± standard error of mean. Statistical analysis was performed with Student's t-test using GraphPad Prism 6 (GraphPad Software Inc., United States) and SPSS 25 (IBM Corp., United States). Two-tailed p-values were used for all analyses, and a p-value < 0.05 was considered statistically significant. Transcriptome analysis was performed using Novomagic (Novogene, China). Pearson analysis was used to correlate gene expression determined by RNA-seq and qRT-PCR.

Sequence Analysis and Truncated Peptides Design
The full-length cDNA sequence of Sparamosin was obtained (Genbank accession number MH423837). This gene consists of a 5 untranslated region (UTR) of 181 bp, an open reading frame (ORF) of 231 bp and a 3 UTR of 161 bp. The ORF of Sparamosin encodes a 76-amino acid protein, which contains a putative 22-amino acid signal peptide and a 54-amino acid mature peptide ( Figure 1A). No similar nucleotide or amino acid sequence was found to match this sequence in the existing online databases, indicating that it is an uncharacterized protein. Two truncated peptides, Sparamosin 1−25 and Sparamosin 26−54 (which located in the 1st to 25th and 26th to 54th amino acid of the mature peptide, respectively), were designed and synthesized based on the secondary structure of Sparamosin mature peptide, which has two predicted α-helices located at residues Ile 13 -Phe 24 and residues Pro 31 -Arg 39 , respectively (Figures 1B,C).
The key physicochemical parameters of Sparamosin and its truncated peptides were shown in Figure 1D. In addition, the peptide sequences of Cecropin A (Steiner et al., 1981), Magainin II (Zasloff, 1987), and LL-37 (Gudmundsson et al., 1996) were also analyzed as comparative controls. The measured molecular weights of Sparamosin and its truncated peptides were consistent with their theoretical values, indicating that these peptides were successfully synthesized. The hydrophobic residue ratio of six peptides ranged from 32 to 45%, the net charge ranged from −3 to + 6, and the hydrophobic moment ranged from 0.105 to 0.521. The results showed that unlike the other two synthetic peptides (Sparamosin and Sparamosin 1−25 ), the physicochemical parameters of Sparamosin 26−54 have values closer to those defined for AMP.

The Truncated Peptide Sparamosin 26−54 Has Potent and Broad-Spectrum Antimicrobial Activity Without Cytotoxicity
Our preliminary study on six commercially available CGMCC strains showed that Sparamosin 26−54 displayed stronger antimicrobial activity than Sparamosin, while no antimicrobial activity of Sparamosin 1−25 was observed in the tested strains (Supplementary Table 3). Then, we further evaluated the antimicrobial efficacy of Sparamosin 26−54 by determining its MIC, MBC and MFC against a series of strains. As shown in Table 1, Sparamosin 26−54 displayed a broadspectrum antibacterial activity against several Gram-negative (P. fluorescens, P. stutzeri, P. fluorescens, A. baumannii, E. coli) and Gram-positive (S. aureus, S. epidermidis, B. cereus, E. faecium, E. faecalis) bacteria with MIC values in the range of 6-48 µM, as well as the MBC values lower than 48 µM. In addition, Sparamosin 26−54 showed a profound inhibitory effect against a pathogenic fungus C. neoformans, and could inhibit the conidial germination of several filamentous fungi, such as A. niger, A. fumigatus, F. graminearum, and F. oxysporum with MIC values in the range of 6-24 µM. However, it was not cytotoxic to mammalian cells tested (AML12 and L02 cells) (Supplementary  Figures 1A,B), indicating that Sparamosin 26−54 had good biocompatibility.
Sparamosin 26−54 Has Anti-biofilm Activity Against C. neoformans Since Sparamosin 26−54 showed good activity against planktonic C. neoformans cells, we further evaluated whether Sparamosin 26−54 could inhibit C. neoformans biofilm formation. The biofilm mass of C. neoformans was quantified by CV staining, and the results were shown in Figures 2A,B. The concentration of Sparamosin 26−54 required to inhibit C. neoformans biofilm formation was 12 µM. At a concentration of 48 µM, the inhibition rate of biofilm formation was more than 90%. In addition, we used the redox indicator resazurin to monitor the respiratory activity of the preformed C. neoformans biofilms treated with Sparamosin 26−54 . The results showed that Sparamosin 26−54 could inhibit the respiration of C. neoformans in preformed biofilms. At a concentration of 48 µM, the inhibition rate of respiratory activity exceeded 50% (Figures 2C,D). These results suggested that Sparamosin 26−54 exhibited potent anti-biofilm activity against C. neoformans.

The Molecular Response of C. neoformans to Sparamosin 26−54
To build a comprehensive model of C. neoformans response to Sparamosin 26−54 , RNA sequencing was used to determine DEGs in response to treatment with a low dose of Sparamosin 26−54 . The predicted secondary structure of Sparamosin mature peptide. There are two predicted α-helices located at residues Ile 13 -Phe 24 and residues Pro 31 -Arg 39 , respectively. (C) The design process of truncated peptide. The red amino acid sequence represents the predicted α-helix structure. (D) The key physicochemical parameters of Sparamosin mature peptide and its truncated peptides, Cecropin A, Magainin II, and LL-37 were calculated by using online tools. Their molecular weight (MW) were measured by electrospray ionization mass spectrometry (ESI-MS).
We obtained 2,573 genes (up-regulated, 1,474; down-regulated, 1,099) and 3,157 genes (up-regulated, 1,602; down-regulated, 1,555) that were differentially expressed after 0.25 × and 0.5 × MIC Sparamosin 26−54 treatment, respectively (Supplementary Tables 4, 5). Overlapping analysis showed that 1,330 genes were commonly up-regulated under both Sparamosin 26−54 concentrations tested, while 1,023 genes were commonly down-regulated under the same conditions ( Figure 3A and Supplementary Tables 6, 7). To further investigate the biological processes involving these up-regulated or down-regulated genes, two DEG lists were separately analyzed for enrichment of GO terms. Genes up-regulated after Sparamosin 26−54 treatment were associated with several significantly enriched biological processes, including cell wall organization or biogenesis, transmembrane transport, lipid oxidation, DNA repair, etc. (Supplementary Table 8). In the biological process category of the down-regulated genes, translation and metabolic processes were significantly enriched (Supplementary Table 8). Figure 3B is a heatmap showing the up-regulated genes involved in the biosynthesis of cell wall component, CWI signaling pathway, anti-oxidative stress, apoptosis and DNA repair, as well as the downregulated genes involved in the ergosterol biosynthesis pathway and mitochondrial oxidative phosphorylation in C. neoformans cells after Sparamosin 26−54 treatment. To verify the RNA-Seq results, a total of 11 genes were selected including 5 up-regulated and 6 down-regulated from DGEs for qRT-PCR analysis. As shown in Figures 3C,D, the qRT-PCR results showed that the expression patterns of selected genes were consistent to those obtained by RNA-seq and the Pearson correlation analysis revealed that these genes were significantly correlated between the RT-qPCR and RNA-seq (Pearson correlation coefficient > 0.98). Thus, the qRT-PCR results confirmed the reliability of the RNA-Seq data.

Sparamosin 26−54 Exerts Its Antifungal Activity Through Targeting Fungal Membrane
In many cases, binding to the surface of fungal cell is the first step for AMPs to kill fungi. Therefore, we hypothesized that Sparamosin 26−54 might directly bind to the cell surface of C. neoformans. To test this hypothesis, the distribution of Sparamosin 26−54 in C. neoformans was investigated by FITC-labeled Sparamosin 26−54 . As shown in Figure 4A, the fluorescence of FITC-labeled Sparamosin 26−54 was mainly located on the cell surface, indicating that Sparamosin 26−54 might interact with the cell walls/membranes. To further determine the binding properties of Sparamosin 26−54 to cell wall or cell membrane components, a modified ELISA assay and chitin-binding assay were performed. The results showed that Sparamosin 26−54 could not bind glucan or chitin (data not shown). Next, we assessed the ability of Sparamosin 26−54 to bind different bioactive membrane phospholipids using the proteinphospholipid interaction assay. As shown in Figures 4B,C, Sparamosin 26−54 strongly bound to phosphoinositides (PIPs) and phosphatidic acid (PA), but weakly bound to a variety of other phospholipids, including lysophosphatidic acid (LPA), lysophosphocholine (LPC), phosphatidylinositol (PI), phosphatidylethanolamine (PE), phosphatidylcholine (PC), sphingosine 1-phosphate (S1P), and phosphatidylserine (PS). These results suggest that Sparamosin 26−54 might bind to fungal cell membrane rather than cell wall. The time-killing curves for Sparamosin 26−54 on C. neoformans was determined at the concentrations of 1 × and 2 × MIC. As shown in Figure 5A, Sparamosin 26−54 showed rapid killing activity against C. neoformans and completely killed the fungus within 10 min. This rapid fungicidal rate indicated that Sparamosin 26−54 might kill C. neoformans by disrupting the integrity of cell membrane. To further evaluate the effect of Sparamosin 26−54 on the permeability of the C. neoformans cell membrane, the release of calcein, DNA and ATP were measured. As shown in Figure 5B, when exposed to Sparamosin 26−54 , calcein leaked from calcein-loaded C. neoformans in a time-and concentration-dependent manner. In addition, Sparamosin 26−54 increased the amount of DNA and ATP detected in the supernatant of the C. neoformans suspensions (Figures 5C,D). Then, we employed SEM and TEM to observe the changes in the morphology and ultrastructure of C. neoformans cells after Sparamosin 26−54 treatment (Figures 6A,B). The SEM images of the peptide-treated cells showed that Sparamosin 26−54 had a morbid effect on C. neoformans cells surface. After treatment with 24 µM Sparamosin 26−54 for 1 h, the surface of the fungal cells became rough and corrugated. In contrast, the control cells that were not treated with Sparamosin 26−54 exhibited a bright and smooth surface. The TEM image of the peptide-treated cells clearly showed the disruption of cell wall and cell membrane and the leakage of intracellular contents, while the fungal cells in the control group showed an intact cell wall and cell membrane and a homogeneous cytoplasm. SYTO 9 can enter all yeasts regardless of their membrane integrity, while PI can only enter yeasts with damaged membranes. Therefore, the integrity of the C. neoformans cell membrane was observed by staining with SYTO 9/PI. As shown in Figure 6C, the untreated cells were stained only with SYTO 9 instead of PI, while cells treated with Sparamosin 26−54 were stained with SYTO 9 and PI. Taken together, these results suggested that Sparamosin 26−54 disrupts the integrity of the cell wall and cell membrane of C. neoformans.

Sparamosin 26−54 Induces Apoptosis in C. neoformans
Among the DEGs identified, a gene coding for a metacaspase was found to be up-regulated under Sparamosin 26−54 treatment, indicating that Sparamosin 26−54 may induce apoptosis in C. neoformans. Thus, we first used DCFH-DA probe to measure intracellular ROS in C. neoformans during exposure to Sparamosin 26−54 . As shown in Figure 7A, cells treated with 20 mM H 2 O 2 as a positive control showed increased DCH staining compared to untreated cells. In accordance with this, cells exposed to Sparamosin 26−54 (6 and 12 µM) displayed a significant increase in intracellular ROS levels compared to untreated cells. These data indicated that Sparamosin 26−54 treatment resulted in the accumulation of ROS in C. neoformans. The dissipation of MMP is considered to be an early and key cellular event in the occurrence of neoformans biofilm. The biofilm mass was quantified by CV staining, and the absorbance at 595 nm was measured. Bc, blank control. (C,D) The inhibitory effect of Sparamosin 26−54 against the preformed biofilm of C. neoformans. The amount of reduced resazurin (resorufin) was determined by measuring the absorbance at 560 nm, and the residual amount of oxidized resazurin was quantified by measuring the absorbance at 620 nm. The corrected A 560 value (AR 560 ) was calculated using the following formula: AR 560 = A 560 − (A 620 × R O ) and R O = AO 560 /AO 620 , where A 560 and A 620 are sample absorbance and AO 560 and AO 620 are the absorbance of RPMI-MOPS medium containing 0.1 mM resazurin. Bc, blank control. Data represent mean ± standard error of mean from three independent biological replicates. Significant difference between control group and Sparamosin 26−54 treatment group was indicated by asterisks as **p < 0.01; ***p < 0.001. apoptosis (Barroso et al., 2006). To investigate mitochondriamediated pathway during apoptosis in C. neoformans induced by Sparamosin 26−54 , we next examined MMP of C. neoformans by using DiOC 6 (3) which is a membrane potential-sensitive dye that aggregating in healthy mitochondria. After treatment with 6 and 12 µM Sparamosin 26−54 for 3 h, MMP was observed by the decrease of the fluorescence intensity of DiOC 6 (3), indicating that Sparamosin 26−54 disrupted the MMP of C. neoformans (Figure 7B). To obtain more evidence of apoptosis in C. neoformans induced by Sparamosin 26−54 , the TUNEL assay was conducted, which is one of the most reliable methods for identifying the late stage of yeast cell apoptosis, and is used to visualize the amount of DNA fragmentation in individual cells. We used amphotericin B as a positive control because it has been proven to induce apoptosis in C. neoformans cells (Castro et al., 2018). The microscopic images showed the presence of green fluorescence in the cells treated with 6 and 12 µM Sparamosin 26−54 , which was consistent with the positive control cells treated with 4 µg/mL amphotericin B (Figure 7C). Since accumulation, MMP dissipation and DNA fragmentation are all hallmarks of apoptosis (Munoz et al., 2012), our data collectively confirmed that C. neoformans treated with Sparamosin 26−54 exhibited apoptosis mechanism.

DISCUSSION
C. neoformans is an important fungal pathogen, causing lifethreatening pneumonia and meningitis in immunocompromised patients. However, the existing treatment options for cryptococcosis have been hampered by their inherent toxicity to humans and the increase in their drug-resistance. This situation urgently requires the development of novel antifungal agents. Due to the broad-spectrum antimicrobial activities and unique mode of action against human pathogens, natural AMPs have attracted more and more attention as potential alternatives for  The densitometry analysis of PIP Strips TM probed with Sparamosin 26−54 by Image J software. Data represent mean ± standard error of mean from three independent biological replicates. Significant difference between blank group and cellular lipids group was indicated by asterisks as *p < 0.05; **p < 0.01; ***p < 0.001. LPA, lysophosphatidic acid; LPC, lysophosphocholine; PI, phosphatidylinositol; PI(3)P, phosphatidylinositol (3)-phosphate; PI(4)P, phosphatidylinositol (4)-phosphate; PI(5)P, phosphatidylinositol (5)-phosphate; PE, phosphatidylethanolamine; PC, phosphatidylcholine; S1P, sphingosine 1-phosphate; PI(3,4)P 2 , phosphatidylinositol (3,4)-bisphosphate; PI(3,5)P 2 , phosphatidylinositol (3,5)-bisphosphate; PI(4,5)P 2 , phosphatidylinositol (4,5)-bisphosphate; PI(3,4,5)P 3 , phosphatidylinositol (3,4,5)-trisphosphate; PA, phosphatidic acid; PS, phosphatidylserine. conventional antibiotics. To date, over 3,000 natural AMPs have been found (antimicrobial peptide database 3, APD3) (Wang et al., 2016). In the past few decades, dozens of AMPs have been identified from the mud crab S. paramamosain, such as crustins, anti-lipopolysaccharide factors, and several gonadal-specific AMPs including scygonadin, SCY2 and scyreprocin (Huang et al., 2006;Wang et al., 2007;Qiao et al., 2016;Wang et al., 2018;Yang et al., 2020;Long et al., 2021). In the study, we identified a novel AMP named Sparamosin from S. paramamosain, and found that its truncated peptide Sparamosin 26−54 showed broad-spectrum antimicrobial activity. Furthermore, Sparamosin 26−54 exerts potent inhibitory effect against the three infection forms of C. neoformans (that is, planktonic cells, biofilm formation and preformed biofilm). It has multiple antifungal mechanisms against C. neoformans, including disruption of the cell wall and cell membrane integrity and induction of apoptosis. Transcriptome analysis showed that after Sparamosin 26−54 treatment, the expression of genes related to cell wall component biosynthesis, CWI signaling pathway, anti-oxidative stress, apoptosis, DNA repair, ergosterol biosynthesis pathway and mitochondrial oxidative phosphorylation were significantly modulated in The concentration of extracellular ATP in C. neoformans after Sparamosin 26-54 treatment. The amount of extracellular ATP was detected using the ATP determination kit. Data represent mean ± standard error of mean from three independent biological replicates. Significant difference between control group and Sparamosin 26-54 treatment group was indicated by asterisks as **p < 0.01; ***p < 0.001. C. neoformans. These obtained results provide important reference for the further development of Sparamosin 26−54 as a new antifungal drug.
Sequence modification is an effective strategy to improve the performance of natural AMPs. Various sequence modification methods attempted to modify natural AMPs by deleting, adding, or replacing one or more amino acid residues, truncating peptides, or assembling chimeric peptides from fragments of different natural AMPs. Many AMPs, such as cecropins, LL-37, magainins, and melittins, are finally obtained through sequence modification (Oh et al., 2000;Wu et al., 2014;Wang et al., 2019). Due to the synthetic mature peptide of Sparamosin exerts moderate inhibitory effect against bacteria and fungi, two truncated peptides, Sparamosin 1−25 and Sparamosin 26−54 , were designed and synthesized based on the secondary structure and physicochemical parameters of Sparamosin. Through predicting the secondary structure of Sparamosin, we found that there were two α-helices located at residues Ile 13 -Phe 24 and residues Pro 31 -Arg 39 , respectively. The α-helical AMPs, such as cecropin, magainin and LL-37, are one of the most widely studied AMPs (Beevers and Dixon, 2010;Nguyen et al., 2011). Many of these α-helical AMPs are usually cationic and amphipathic with potent antimicrobial activities against bacteria and fungi (Hancock and Sahl, 2006). The mechanism of action of α-helical AMPs is mainly composed of two steps, that is, the initial binding of cationic AMPs with the negatively charged components on the microbial cell surface and the subsequent membrane disruption (Huang, 2000;Beevers and Dixon, 2010). The crucial physicochemical parameters of peptides were calculated by using online tools. In this study, the hydrophobic residue ratio of Sparamosin and its truncated peptides ranged from 32 to 38%, and the net charge varied from −3 to + 6. Hydrophobicity is defined as the percentage of hydrophobic residues in the peptide and is an important parameter to determine the activity of AMPs. The hydrophobicity exceeds a threshold to confer antimicrobial activity, and there is an upper limit, beyond which the host cells will rupture and cell selectivity will be lost (Frederiksen et al., 2020). Therefore, the percentage of hydrophobic residues in AMPs characterized to date is approximately 40-60% (Tossi et al., 2000). Cationicity is another important parameter that affects the antimicrobial activity of AMPs. Most AMPs are positively charged, and charges from + 4 to + 6 seem to be the most common (Tossi et al., 2000). Within a certain range, an increase in the total charge of cationic peptides will often lead to an increase in affinity for microbial membranes, thereby enhancing their antimicrobial activity (Dathe et al., 2001). It should be noted that hydrophobicity and cationicity are not independent, they complement each other and together determine the antimicrobial activity of AMPs. Among Sparamosin and its truncated peptides, Sparamosin 1−25 has no antimicrobial activities against the tested strains, and Sparamosin 26−54 displayed stronger antimicrobial activity than Sparamosin. Compared with Sparamosin, the hydrophobic residue ratio of the Sparamosin 26−54 increased from 35 to 38%, and the net charge increased from + 3 to + 6, which might the main reason why its activity is stronger than Sparamosin. The underlying mechanism still need further evidence.
It is noteworthy that Sparamosin 26−54 also showed excellent anti-biofilm activity against C. neoformans. In the present study, we found that Sparamosin 26−54 could effectively prevent the formation of biofilm, presumably due to the reduction of the planktonic population, and cause the damage to the growth of preformed biofilms through a strong inhibition of respiration. A biofilm is an organized aggregate of microbial cells that attached to a solid surface and enclosed in an extracellular polymeric substance matrix (Donlan, 2002). C. neoformans is a yeast-like fungus with polysaccharide capsules that can form biofilms on polystyrene plates and medical devices (Martinez and Casadevall, 2005). The biofilm formation of C. neoformans includes fungal surface adhesion, microcolony formation, and matrix production (Martinez and Casadevall, 2005). Fungal cells within biofilms display unique phenotypic characteristics that can increase the resistance to the host's immune system and antifungal agents (Lilit et al., 2017;Kean and Ramage, 2019). Azole drugs such as voriconazole and fluconazole can only effectively inhibit planktonic fungal cells, but have little effect on fungal biofilms (Martinez and Casadevall, 2006). Amphotericin B and caspofungin are the two most effective drugs for preventing the formation of C. neoformans biofilm and against mature biofilms (Martinez and Casadevall, 2006). However, the effective concentration of amphotericin B and caspofungin against C. neoformans biofilm is higher than the therapeutic range, thus causing serious toxicity (Martinez and Casadevall, 2006;Delattin et al., 2014). In fact, most of the currently available antibiotics are unable to address chronic infections caused by biofilm effectively (Roy et al., 2018;Vuotto and Donelli, 2019). In addition to broad-spectrum bactericidal and fungicidal activities, more and more evidences showed that AMPs can also exhibit anti-biofilm activity against both bacterial and fungal biofilm in three different ways by reducing planktonic population, preventing cells from initially adhering to the surface, and eradicating established biofilms. For example, a shortened variant of mouse cathelicidin-related AMP, termed AS10, inhibits the formation of C. albicans biofilms, and acts synergistically with common antifungal drugs (such as amphotericin B and caspofungin) against mature biofilms   De Brucker et al., 2014). The mud crab AMP Scyreprocin could not only inhibit the biofilm formation, but also eradicate mature biofilms of C. albicans and C. neoformans . Therefore, the research and development of AMPs with anti-biofilm activity has more clinical significance. The anti-biofilm mechanism of Sparamosin 26−54 and the efficacy of Sparamosin 26−54 combined with standard antifungal drugs is worthy of further study.
The proposed antifungal mechanisms of AMPs are diverse, including cell wall integrity disruption, cell membrane permeabilization as well as apoptosis induction (Hwang et al., 2011b;Cho et al., 2012;Ma et al., 2020). Many studies have also shown that AMPs and pore-forming toxins have a similar mechanism of action, that is, the formation of holes in the cell membrane (Gilbert et al., 2014;Etxaniz et al., 2018). It has been reported that pore-forming toxins could trigger very diverse response pathways in eukaryotic cells (Gonzalez et al., 2011;Kao et al., 2011). When the plasma membrane is damaged by pore-forming toxins, cells activate signaling pathways to restore plasma membrane integrity and ion homeostasis (Gonzalez et al., 2011). In addition, pore-forming toxins can induce cell death by inducing apoptosis and pyrophosis (Genestier et al., 2005;Shoma et al., 2008). To investigate the antifungal mechanism of Sparamosin 26−54 , we used RNA-Seq to study the transcriptomic profile of C. neoformans treated with sublethal concentrations of Sparamosin 26−54 . As reported previously, sublethal concentrations of AMPs can lead to fungal cell dysfunction. For example, the plant defensin HsAFP1 at 2 × FC50 (FC50, fungicidal concentration resulting in 50% killing) induces autophagy, vacuolar dysfunction and cell cycle impairment in C. albican (Struyfs et al., 2020). The Musca domestica antifungal peptide-1 (MAF-1) at 1 × MIC induces the expression of genes related to oxidative stress response and cell wall synthesis and inhibits the expression of genes related to metabolism and fatty acid biosynthesis in C. albican (Wang et al., 2017). In the study, C. neoformans cells were incubated with different concentrations of Sparamosin 26−54 (0.25 × MIC, 0.5 × MIC) for 1 h before RNA sequencing. We compared the differential gene-expression profile of Sparamosin 26−54 treatment at 0.25 × MIC and 0.5 × MIC to the untreated control to identify a set of genes commonly perturbed by Sparamosin 26−54 treatment. This analysis revealed that genes involved in the biosynthesis of cell wall component, CWI signaling pathway, anti-oxidative stress, apoptosis and DNA repair were upregulated under Sparamosin 26−54 treatment, while genes associated with the ergosterol biosynthesis pathway and mitochondrial oxidative phosphorylation were downregulated under the same condition. It is not clear which genes or signaling pathways are specifically involved in the cellular response to Sparamosin 26−54 . The use of inhibitors or regulators of specific signaling pathways to demonstrate the involvement of pathways in the cell death process deserves further investigation.
We propose that cellular changes and damage initiated through interaction with primary targets of Sparamosin 26−54 result in activation of intracellular signaling pathways. Fungal cell membrane is potential target for AMPs and is rich in a variety of lipids such as glycerophospholipids, sphingolipids and sterols. In this study, we identified the glycerophospholipid targets of Sparamosin 26−54 as PIPs and PA. In addition, the rapid fungicidal effect of Sparamosin 26−54 against C. neoformans was associated with increased plasma membrane permeability, which can be detected by releasing calcein from fungal cells, leaking DNA and ATP to the supernatant, and positively staining yeasts with PI, and observed by SEM and TEM. Thus, it could be speculated that the binding of Sparamosin 26−54 to PIPs and PA induces the membrane permeability of C. neoformans. PIPs are usually found on the inner leaflet of eukaryotic cells and play a major role in many important membrane-related processes, such as signal transduction, ion channel function, endocytosis, exocytosis, etc. (McLaughlin and Murray, 2005). Although PIPs commonly exist in eukaryotic cells, the relative contributions of negative and neutral glycerophospholipids in cell membrane of fungi and mammal are different (Rautenbach et al., 2016). Generally, fungal cell membranes are mainly composed of PI and PS, which tend to be high electronegative, while mammalian cell membranes rich in zwitterionic phospholipids PC are usually neutral in net charge (Rautenbach et al., 2016). These electrostatic differences between fungi and mammalian cells may allow a stronger initial electrostatic interaction between the cationic AMPs and the fungal cell surface. Certain plant defensins have been observed to bind PIPs preferentially. For example, the Nicotiana alata defensin NaD1 could bind to a wide range of PIPs, while the tomato defensin TPP3 specifically bound to PI(4,5)P 2 (Baxter et al., 2015;Payne et al., 2016). The binding of NaD1 to PI(4,5)P 2 leads to the formation of an oligomeric complex, that is critical for cytolytic activity (Poon et al., 2014). This unique peptide-lipid interaction was common in plant defensins, which may be one of the important mechanisms of plants against fungal infection. Interestingly, we found that AMPs from marine animal and plant have the similar binding properties to membrane phospholipid, suggesting that Sparamosin 26−54 and plant defensins have similar mechanisms of action. Further studies are needed to understand the role of phospholipids binding in Sparamosin 26−54 -induced membrane permeabilization of C. neoformans.
In addition to the membrane disruption, some AMPs can also induce oxidative stress, DNA damage and apoptosis in yeasts (Cho and Lee, 2011;Hwang et al., 2011a,b). ROS, such as hydrogen peroxide (H 2 O 2 ), hydroxyl radicals (OH·) and superoxide anions (O 2 − ), are considered to be early signal mediators of apoptosis (Fleury et al., 2002). The ROS produced by aerobic metabolism usually exist in cells in balance with antioxidant enzymes (such as catalase, superoxide dismutase, and glutathione peroxidase) (Dantas et al., 2015). Previous studies have shown that the increase in ROS upon AMPs treatment also occurs in fungi, which supports our findings (Hwang et al., 2011a;Wang et al., 2015). Excessive ROS has multiple deleterious effects on the essential structures of fungi (such as nucleic acid, DNA, amino acid residues, and cell membrane) resulting in cell death (Perrone et al., 2008). Mitochondria play an important role in energy conversion, cell signaling and apoptosis pathway (Turrens, 2003). The cell permeability and lipophilic dye, DiOC 6 (3), which accumulates in healthy mitochondria and is widely used to investigate the mitochondria-mediated pathways during apoptosis (Zamzami et al., 1996;Kataoka et al., 2005). Our present study demonstrated that after treatment with Sparamosin 26−54 , DiOC 6 (3) dye no longer accumulated in mitochondria, resulting in a decrease in green fluorescence, suggesting that Sparamosin 26−54 might lead to the opening of mitochondrial membrane transition pores and induce the dissipation of the MMP. The dysfunction of mitochondria leads to an energy crisis and promotes the release of proapoptotic factors from mitochondria into the cytosol, which then activates caspase (Heiskanen et al., 1999;Pereira et al., 2007). During apoptosis, chromatin DNA is cut into small fragments by the activation of endonucleases, which is an irreversible step of apoptosis. The labeling and observation of DNA fragmentation by TUNEL assay is one of the most reliable methods to identify the phenotype of late apoptosis in yeasts (Ribeiro et al., 2006). Taken together, our comprehensive physiological effect data (including ROS accumulation, MMP dissipation and DNA fragmentation) indicated that Sparamosin 26−54 induced apoptosis in C. neoformans.
In summary, the present study demonstrated the antifungal activity and related mechanism of Sparamosin 26−54 , which is a novel AMP found in mud crab S. paramamosain. The synthetic Sparamosin 26−54 showed potent activity against three infection forms of C. neoformans (planktonic, biofilm formation and preformed biofilm). It was confirmed that this peptide can effectively kill C. neoformans via multiple modes of action, including disrupting the integrity of the cell wall and cell membrane and inducing apoptosis. These results indicated that the novel AMP Sparamosin 26−54 is expect to be a promising antifungal drug that could be used to control C. neoformans infection in the future.

DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi. nlm.nih.gov/, PRJNA751241. The GenBank accession number is MH423837.

AUTHOR CONTRIBUTIONS
K-JW and FC: conceptualization, funding acquisition, project administration, supervision, and writing-review and editing. Y-CC: data curation, formal analysis, investigation, methodology, and writing-original draft. YY, CZ, and H-YC: investigation and methodology. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS
We thank laboratory engineers Hui Peng and Zhiyong Lin for providing technical assistance.